• Royalty Pharma PLC RPRX.OQ reported quarterly adjusted earnings of $1.15​​ per share for the quarter ended December 31, identical to the same quarter last year. The mean expectation of seven analysts for the quarter was for earnings of $1.05 per share. Wall Street expected results to range from 65 cents to $1.24 per share.

• Revenue fell 0.3% to $594.00 million from a year ago; analysts expected $678.89 million.

• Royalty Pharma PLC's reported EPS for the quarter was 35 cents​.

• The company reported quarterly net income of $208 million.

• Royalty Pharma PLC shares had risen by 24.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 6.9% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Royalty Pharma PLC is $40.50

This summary was machine generated from LSEG data February 11 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)